Sincere Capital

Sincere Capital invests across two core thematic areas: technologies that improve industrial efficiency and innovations that enhance human health. This translates into a portfolio concentrated on hard-tech sectors — semiconductor, advanced manufacturing, new materials — and life sciences, including biotechnology and medical devices. The firm pursues these themes through a flexible strategy that spans early-stage venture, growth equity, buyouts, and PIPE deals.

Sincere Capital does not limit itself to a single stage or instrument type. The firm deploys capital across seed, start-up, growth, late-stage expansion, and buyout transactions, and it also participates in private investments in public equity. This multi-stage, multi-instrument approach allows it to back companies throughout their lifecycle rather than exiting at a predetermined maturity threshold.

Available information points to a domestic focus. Sincere Capital's headquarters is in Shanghai, and all publicly described investment activity references China's technology and healthcare sectors. The firm has not disclosed international offices or cross-border deal activity.

Sincere Capital's website lists NBFI as a guiding framework, but the firm has not publicly defined the acronym or published detailed methodology. Given the portfolio's concentration on foundational hard technologies and life sciences, NBFI likely structures how the firm evaluates investments in underlying platform technologies with long-term strategic value.

No. Sincere Capital does not publish AUM figures, fund sizes, or capital deployment totals. Without a named external source confirming a specific number, the firm's scale remains undisclosed.